Insulin-mimetic
vanadyl-poly(gamma-glutamic acid) complex,
VO-gamma-PGA, is proposed as a novel drug delivery system for treating type 1 diabetic animals. The structure of
VO-gamma-PGA in
solution as well as in solid state was analyzed by electronic absorption, infra-red, and electron spin resonance spectra, and proposed that the equatorial coordination mode of VO(2+) is in either carboxylate(O)-VO-(OH(2))(3) or 2 carboxylate(O(2))-VO-(OH(2))(2). In vitro
insulin-mimetic activity, metallokinetic feature in the blood of healthy rats, and in vivo normoglycemic effect of the complex prepared in
solution were evaluated in
streptozotocin(STZ)-induced type 1 diabetic mice, and these effects were compared with those of a
solution containing only VOSO(4) as a positive control. The in vitro
insulin-mimetic activity of
VO-gamma-PGA was examined by determining both inhibition of
free fatty acid (FFA) release and
glucose uptake in isolated rat adipocytes, in which the concentration of
VO-gamma-PGA for 50% inhibition of FFA release was significantly lower than that of VOSO(4). Metallokinetic study suggested that the bioavailability of
VO-gamma-PGA complex was much higher than that of VOSO(4). The complex showed a significant
hypoglycemic activity within at least 4h after a single
oral administration, the effect being sustained for at least 24h. Furthermore,
VO-gamma-PGA normalized the
hyperglycemia in STZ-mice within 3 days when it was given orally at doses of 5-10mgVkg(-1) body mass for 16 days. The improvement in diabetes was also supported by the results on oral
glucose tolerance test, HbA(1c) levels, and blood pressure.